Practicing clinical medicine is challenging and stressful enough without the additional burden of being handcuffed by ever-changing medication formularies.
John J. Miller, MD
Most drugs, after journeying through the various metabolic systems throughout the body, find their exit.
Each moment of each day we make choices that can affect our brain health—our challenge is, without judgment, to increase the choices that promote a healthy brain.
An impressive and ever-expanding research literature exists on the topic of pharmacogenomics. Despite this, only four genes have been vetted as clinically actionable.
Psychiatry has finally crossed into a new paradigm in the treatment of TRD, bringing the glutamate system on board to join the modulation of the monoamine systems.
The controversial question of whether to legalize cannabis has emerged front and center as an important issue that deserves a serious and thoughtful dialogue.
We have come a long way in psychiatry, but we are still at the beginning of the story of understanding the human brain.
Substance use disorders are a common comorbidity in individuals with bipolar disorder. Adding cariprazine to their medication regimen may improve symptoms of both disorders.
Since the choice of treatments for a primary bipolar I disorder major depressive episode versus a unipolar major depressive episode are significantly different, this information will help guide clinicians in how to proceed.
The author explores the significant pharmacokinetic and pharmacodynamic heterogeneity of current antidepressants and reviews the many potential drug targets that exist—with a focus on the serotonin system.